This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
JNJNegative Net Change NVAXNegative Net Change IBBNegative Net Change XBINegative Net Change BBHNegative Net Change
biotechs etfs
Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails
by Zacks Equity Research
Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.
REGNNegative Net Change RHHBYNegative Net Change GILDNegative Net Change LLYNegative Net Change
biotechs pharmaceuticals
Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk
by Zacks Equity Research
Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.
INCYNegative Net Change LLYNegative Net Change GSKNegative Net Change VIRNegative Net Change
biotechs
bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study
by Zacks Equity Research
bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.
VRTXPositive Net Change EDITPositive Net Change CRSPNegative Net Change
biotechs
Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins
by Zacks Equity Research
Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.
ACORPositive Net Change MRNANegative Net Change VRTXPositive Net Change CRSPNegative Net Change
biotechs
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
GILDNegative Net Change AMGNPositive Net Change FPRXPositive Net Change ACADNegative Net Change IMVTPositive Net Change
biotechs pharmaceuticals
BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.
MRNANegative Net Change BDSIPositive Net Change CTMXPositive Net Change ASLNNegative Net Change
biotechs earnings
VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study
by Zacks Equity Research
VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.
PFENegative Net Change MRNANegative Net Change VBIVPositive Net Change BNTXNegative Net Change
biotechs
Immunovant (IMVT) Gains on a Potential Buyout by Roivant
by Zacks Equity Research
Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.
JNJNegative Net Change ALXNPositive Net Change HZNPPositive Net Change IMVTPositive Net Change
biotechs
AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure
by Zacks Equity Research
AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.
JNJNegative Net Change GSKNegative Net Change BMYNegative Net Change ANABNegative Net Change
biotechs
Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA
by Zacks Equity Research
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.
RGENNegative Net Change ARCTNegative Net Change RARENegative Net Change STOKNo Net Change
biotechs
ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA
by Zacks Equity Research
The FDA identifies deficiencies in ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock sinks.
RGENNegative Net Change ACADNegative Net Change NBRVPositive Net Change STOKNo Net Change
biotechs
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.
RHHBYNegative Net Change PFENegative Net Change BMRNNegative Net Change SGMOPositive Net Change
biotechs
Surface Oncology (SURF) is Oversold: Can It Recover?
by Zacks Equity Research
Surface Oncology (SURF) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
SURFPositive Net Change
biotechs medical
5 Stocks to Watch Amid Continued Expansion in the Biotech Industry
by Kaustav Ghosh
The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)
REGNNegative Net Change BMYNegative Net Change VRTXPositive Net Change NVAXNegative Net Change ABBVNegative Net Change
biotechs medical
Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL
by Zacks Equity Research
Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.
GILDNegative Net Change NVSNegative Net Change BMYNegative Net Change ALLOPositive Net Change
biotechs
Cara Therapeutics' (CARA) Korsuva NDA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.
RGENNegative Net Change NBRVPositive Net Change STOKNo Net Change
biotechs
Why Five Prime Therapeutics (FPRX) Might Surprise This Earnings Season
by Zacks Equity Research
Five Prime Therapeutics (FPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FPRXPositive Net Change
biotechs earnings
Moving Average Crossover Alert: Innoviva
by Zacks Equity Research
Innoviva (INVA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
INVANegative Net Change
biotechs
Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?
by Kevin Cook
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.
JNJNegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs coronavirus pharmaceuticals
Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine
by Zacks Equity Research
Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
NVSNegative Net Change BAYRYNegative Net Change BNTXNegative Net Change CVACNegative Net Change
biotechs pharmaceuticals
Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout
by Zacks Equity Research
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.
BMYNegative Net Change AMGNPositive Net Change SGENPositive Net Change FPRXPositive Net Change
biotechs
ETFs to Tap Amgen's Drive for Cancer Deal
by Sweta Killa
Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.
BMYNegative Net Change AMGNPositive Net Change IBBNegative Net Change FPRXPositive Net Change BBHNegative Net Change PJPNegative Net Change IEIHPositive Net Change
biotechs etfs medical pharmaceuticals
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care
by Zacks Equity Research
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
ILMNNegative Net Change HOLXNegative Net Change MYGNNo Net Change IDXXNegative Net Change
biotechs medical
Is a Surprise Coming for Castle Biosciences (CSTL) This Earnings Season?
by Zacks Equity Research
Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CSTLNegative Net Change
biotechs medical